BioPharmX (NASDAQ:BPMX) Director Stephen Morlock purchased 428,571 shares of the company’s stock in a transaction that occurred on Monday, November 28th. The stock was bought at an average price of $0.35 per share, with a total value of $149,999.85. Following the transaction, the director now owns 543,956 shares of the company’s stock, valued at approximately $190,384.60. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

BioPharmX (NASDAQ:BPMX) traded up 1.814% on Tuesday, reaching $0.275. The company had a trading volume of 205,621 shares. BioPharmX has a 1-year low of $0.19 and a 1-year high of $2.75. The firm’s market capitalization is $8.57 million. The company’s 50-day moving average price is $0.29 and its 200 day moving average price is $0.58.

TRADEMARK VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this story can be read at

Separately, HC Wainwright reiterated a “buy” rating on shares of BioPharmX in a research report on Saturday, September 17th.

BioPharmX Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

5 Day Chart for NASDAQ:BPMX

Receive News & Stock Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related stocks with our FREE daily email newsletter.